BioInformatics Role in Discovery of New Compounds: deCODE Submits IND for Novel Anti-atherosclerosis Compound DG041 ...
From PR Newswire (press release) ... drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics,
bioinformatics, genotyping, structural biology ...
... deCODE genetics (Nasdaq: DCGN) has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for DG041, a novel, first-in-class, orally-administered small molecule for the treatment of peripheral arterial occlusive disease (PAOD). In preclinical studies, DG041 has been shown to be a selective and potent antagonist of the EP3 receptor for prostaglandin E2 (PGE2), inhibiting, in a dose-dependent manner, human platelet aggregation induced in vitro by PGE2. deCODE identified EP3 as a target in PAOD through its population genetics research, which linked variations in the gene encoding EP3 to a significantly increased risk of the disease. Pending clearance by the FDA, deCODE intends to initiate a Phase I clinical trial of DG041 this spring. ...
Through its population genetics research in Iceland, deCODE identified common versions of the gene encoding EP3 (the PTGER3 gene) that confer significantly increased risk of PAOD. These variants are believed to increase susceptibility to the disease through heightened expression of EP3. Functional analysis underscores the important role of EP3 in modulating the biology of the platelet and the vessel wall. Binding of PGE2 to EP3 is known to increase platelet aggregation, and EP3 is expressed in smooth muscle cells found in atherosclerotic plaque. DG-041 is a novel, selective and potent antagonist of the EP3 receptor. In preclinical in vitro studies it has been shown to inhibit human platelet aggregation induced by PGE2, and to do so in a dose-dependent manner. Furthermore, ex-vivo inhibition of rat platelet aggregation can be demonstrated after oral dosing with DG041. In mice, DG041 has been shown to protect against intravascular coagulation in a model based on prostanoid-induced platelet activation. DG041 has been shown to have minimal effect on bleeding time in animal studies, nor does it inhibit the effect of other platelet agonists such as adenosine diphosphate (ADP), collagen, thrombin or epinephrine.
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics.(SM)
Additional resources on bioinformatics use in discovery of novel compounds ...
FutureBioJobs: Structural Bioinformatics IT solutions unifying genomics and ... the biological activity of a pharmaceutical compound. ... the rapid identification of novel genes and ...
Genomics, Bioinformatics and Proteomics: Genomics - Guide to Genomics, Bioinformatics and Proteomics. ... is that many of the novel genome-derived ... The compound-protein complexes are then split apart using ...
Job Details: Discovery Job #: PSYO-MATIC As the Director of Bioinformatics for PsychoGenics ... your research will significantly reduce the cost per novel compound screened thus ...
Sequoia: high-throughput screening and bioinformatics into an ... than 100 compounds with novel chemical structures ... In addition to developing compound libraries, Sequoia is ...
Targeting Microbes: invaluable resource in the search for novel compounds. ... through a combination of bioinformatics, transcriptional analysis ... is changing from compound screening to ...
Labels: approach, class, job, pharmaceutical, variation